Cargando…
The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
Autores principales: | Huntgeburth, Michael, Kießling, Johannes, Weimann, Gerrit, Kiepsel, Verena, Saleh, Soundos, Hunzelmann, Nicolas, Rosenkranz, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565089/ http://dx.doi.org/10.1186/2050-6511-16-S1-A58 |
Ejemplares similares
-
The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015) -
Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015) -
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015) -
Platelet inhibitory effects of the NO independent sGC stimulator riociguat (Bay 63-2561)
por: Reiss, Cora, et al.
Publicado: (2013) -
Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
por: Saleh, Soundos, et al.
Publicado: (2015)